Journal article

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer

Hui-Ming Lin, Iva Nikolic, Jessica Yang, Lesley Castillo, Niantao Deng, Chia-Ling Chan, Nicole Yeung, Eoin Dodson, Benjamin Elsworth, Calan Spielman, Brian Lee, Zoe Boyer, Kaylene Simpson, Roger Daly, Lisa Horvath, Alexander Swarbrick

Published : 2018


Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously. Therefore, synthetic microRNAs may have therapeutic potential in CRPC by regulating genes involved in taxane response and minimise compensatory mechanisms that cause taxane resistance. To identify microRNAs that can improve the efficacy of taxanes in CRPC, we performed a genome-wide screen of 1280 microRNAs in the CRPC cell lines PC3 and DU145 in combination with docetaxel or cabazitaxel treatment..

View full abstract

University of Melbourne Researchers

Citation metrics